🟢 Neurosense Therapeutics is trading 12.1% up today after HC Wainwright initiated coverage with $8.00 target

Neurosense Therapeutics is trading 12.1% up at $0.45 after HC Wainwright initiated coverage on September 3, 2026, with a Buy rating and an $8.00 price target.

• The analyst action followed the company’s August 31 announcement of an accelerated, capital-efficient PrimeC development strategy for ALS.
• Neurosense Therapeutics plans to file with Health Canada in December 2026.
• The move is company-specific, with broader U.S. indices mixed on September 4, 2026.